Role of pro- and anti-inflammatory cytokines during inflammation: Experimental and clinical findings

Journal of Biological Regulators and Homeostatic Agents

Volumn 11, Issue 3, 1997, Pages 91-103

  Dinarello, C A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Interleukin 1; Interleukin 10; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; BRADYKININ; CORTICOSTEROID; CYTOKINE; EPIDERMAL GROWTH FACTOR; FATTY ACID; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CYTOKINE RELEASE; ENZYME ACTIVITY; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PLEIOTROPY; REVIEW;

ANIMALIA;

EID: 0031471921     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
2. Harada A, Mukaida N, Matsushima K. Interleukin-8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 1996; 2: 482-9.
3. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141-52.
4. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluoruracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420-7.
5. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer J Clin Oncol 1987; 5: 1942-51.
6. van der Poll T, Bueller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
7. van der Poll T, van Deventer SJH, Hack CE, et al. Effects of leukocytes following injection of tumor necrosis factor into healthy humans. Blood 1991; 79: 693-8.
8. Porat R, Poutsiaka DD, Miller LC, et al. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J 1992; 6: 2482-6.
9. Kaplanski G, Porat R, Aiura K, et al Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993; 81: 2492-5.
10. Holtmann H, Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139: 1161-7.
11. Brakebusch C, Varfolomeev EE, Batkin M, et al. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem 1994; 269: 32488-96.
12. O'Neill LAJ, Bird TA, Saklatvala J. Interleukin-1 signal transduction. Immunol Today 1990; 11: 392-4.
13. Mizel SB. Cyclic AMP and interleukin-1 signal transduction. Immunol Today 1990; 11: 390-1.
14. Munoz E, Beutner U, Zubiaga A, et al. IL-1 activates two separate signal transduction pathways in T helper type II cells. J Immunol 1990; 144: 964-9.
15. Rosoff PM, Savage N, Dinarello CA. Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism. Cell 1988; 54: 73-81.
16. Kester M, Siomonson MS, Mene P, et al. Interleukin-1 generate transmembrane signals from phospholipids through novel pathways in cultured rat mesangial cells. J Clin Invest 1989; 83: 718-23.
17. Mathias S, Younes A, Kan C-C, et al. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science 1993; 259: 519-22.
18. 2 by phosphorylation in rat mesangial cells. J Clin Invest 1994; 93: 1224-33.
19. 2-activating protein. Proc Natl Acad Sci USA 1991; 88: 5418-22.
20. Kracht M, Truong O, Totty NF, et al. Interleukin-1α activates two forms of p54α mitogen-activated proetin kinase in rabbit liver. J Exp Med 1994; 180: 2017-27
21. Guesdon F, Waller RJ, Saklatvala J. Specific activation of β-casein kinase by the inflammatory cytokines interleukin-1 and tumour necrosis factor. Biochem J 1994; 304: 761-8.
22. Freshney NW, Rawlinson L, Guesdon F, et al. Interleukin-1 activates a novel protein cascade that results in the phosphorylation of hsp27. Cell 1994; 78: 1039-49.
23. Guesdon F, Freshney N, Waller RJ, et al. Interleukin 1 and tumor necrosis factor stimulate two novel protein kinases that phosphorylate the heat shock protein hsp27 and beta-casein. J Biol Chem 1993; 268: 4236-43.
24. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
25. Kunz D, Mühl H, Walker G, et al. Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat mesangial cells. Proc Natl Acad Sci USA 1994; 91: 5387-91.
26. Szabo C, Wu C-C, Gross SS, et al. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993; 150: 157-60.
27. Salvemi D, Misko TP, Masferrer JL, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4.
28. Palmer RM, Hickery MS, Charles IG, et al. Induction of nitric oxide synthase in human chrondrocytes. Biochem Biophys Res Commun 1994, 193: 398-405.
29. Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition J Clin Invest 1988; 81: 1162-1172.
30. Fischer E, Marano MA, Barber AE, et al. A comparison between the effects of mterleukin-1α administration and sublethal endotoxemia in primates. Am J Physiol 1991; 261: R442-R449.
31. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87: 602-8.
32. Tredget EE, Yu YM, Zhong S, et al. Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol 1988; 255: E760-E768.
33. Evans DB, Bunning RA, Russell RG. The effects of recombinant IL-1 beta on cellular proliferation, and the production of PGE, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun 1990; 166: 208-16.
34. Krane SM, Conca W, Stephenson ML, et al. Mechanisms of matrix degradation in rheumatoid arthritis. Ann N Y Acad Sci 1990; 580: 340-54.
35. Dayer JM, de Rochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77: 645-8.
36. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81: 487-98.
37. Rock CS, Coyle SM, Keogh CV, et al. Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery 1992; 112: 467-74.
38. Santos AA, Scheltinga MR, Lynch E, et al. Elaboration of interleukin-1 receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 1993; 128: 138-44.
39. Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in neuroendocrine therapy of inflammatory diseases. Mediator Inflamm 1993; 2: 263-70.
40. Meydani SN, Dinarello CA. Influence of dietary fatty acids on cytokine production and its clinical implications. Nutr Clin Pract 1993; 8: 65-72.
41. Endrcs S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-71.
42. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1990; 121: 547-55.
43. Molvig J, Pociot F, Svingen BA, et al. Dietary supplementation with n-3 fatty acids decreases mononuclear proliferation and interleukin-1β content but not monokine secretions in insulindependent diabetic individuals. Scand J Immunol 1991; 34: 399-410.
44. Cooper AL, Gibbons L, Horan MA, et al. Effect of dietary fish oil supplementation on fever and cytokine production in human volunteers. Clin Nutr 1993; 12: 321-8.
45. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunological effects of national cholesterol education panel (NCEP) step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 1993; 92: 105-13
46. Spinas GA, Bloesch D, Keller U, et al. Pretreatment with ibuprofen augments circulating tumor necrosis factor, interleukin-6 and elastase during acute endotoxemia. J Inf Dis 1991; 163:89-95.
47. Endres S, Fuelle H-J, Sinha B, et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunol 1991; 72: 56-60.
48. Beasley D, McGuiggin M. Interleukin-1 induces prostacyclin-dependent increases in cyclic AMP production and does not affect cyclic GMP production in human vascular smooth muscle cells. Cytokine 1995 (in press).
49. Vannier E, Miller LC, Dinarello CA. Histamine suppresses gene expression and synthesis of tumor necrosis factor α via histamine H2 receptors. J Exp Med 1991; 174: 281-4.
50. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells: comparison with IL-1 receptor antagonist. J Clin Invest 1993; 92: 281-7.
51. Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV IFN-γ suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J Immunol 1990; 144: 2216-22.
52. Stevenson FT, Torrano F, Locksley RM, et al. Interleukin-1: the patterns of translation and intracellular distribution support aternative secretory mechanisms. J Cell Physiol 1992; 152: 223-31.
53. Stevenson FT, Bursten SL, Fanton C, et al. The 31-kDa precursor of interleukin-1α is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc Natl Acad Sci USA 1993; 90: 7245-9.
54. Singer II, Scott S, Chin J, et al. Interleukin-1β converting enzyme is localized on the external cell-surface membranes and in the cytoplasmic ground substance of activated human monocytes by immuno-electronmicroscopy (abstract). Lymphokine Cytokine Res 1993; 12: 340.
55. Vannier E, Lefort J, Lellouch-Tubiana A, et al. Lipopolysaccharide from E. coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs. J Clin Invest 1991; 87: 1936-44.
56. 2 receptors in peripheral blood mononuclear cells. J Biol Chem 1994; 269: 9952-6.
57. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
58. Stevenson FT, Bursten SL, Locksley RM, et al Myristyl acylation of the tumor necrosis factor-α precursor on specific lysines. J Exp Med 1992; 176: 1053-62.
59. Chin J, Kostura MJ. Dissociation of IL-1β synthesis and secretion in human blood monocytes stimulated with bacterial cell wass products. J Immunol 1993; 151: 5574-5585.
60. Gu Y, Kuida K, Tsutsui H, et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997; 275: 206-209.
61. Okamura H, Nagata K, Komatsu T, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995; 63: 3966-3972.
62. Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces interferon-y. Nature 1995; 378: 88-91.
63. McGeehan GM, Becherer JD, Bast R, Jr., et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-61.
64. Mohler KM, Sleath PR, Fitzner JN, et al Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
65. Gearing AJH, Beckett P, Christodoulous M, et al. Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 1994; 370: 555-67.
66. Kobayashi Y, Yamamoto K, Saido T, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA 1990; 87: 5548-52.
67. Kobayashi Y, Oppenheim JJ, Matsushima K. Human preinterleukin-1α and β: structural features revealed by limited proteolysis. Chem Pharmaceut Bull 1991; 39: 1513-7.
68. Watanabe N, Kobayashi Y. Selective release of a processed form of interleukin-1α. Cytokine 1994; 6: 597-601.
69. Kaplanski G, Farnarier C, Kaplanski S, et al. Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 1994; 84: 4242-8.
70. Endres S, Cannon JG, Ghorbani R, et al. In vitro production of IL-1β, IL-1α, TNF, and IL-2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19: 2327-33.
71. Schindler R, Mancilla J, Endres S, et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-7.
72. Lonnemann G, Endres S, van der Meer JW, et al. Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur J Immunol 1989; 19: 1531-6.
73. Li P, Allen H, Banerjee S, et al. Mice deficient in interleukin-1 converting enzyme (ICE) are defective in producton of mature interleukin-1β and resistant to endotoxic shock. Cell 1995; 80: 401-11.
74. Kuida K, Lippke JA, Ku G, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 1995; 267: 2000-3.
75. Sirko S, Schindler R, Doyle MJ, et al. Transcription, translation and secretion of interleukin-1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Immunol 1991; 21: 242-50.
76. Young PR, McDonnell PC, Laydon JT, et al. A novel MAP kinase regulates the production of IL-1 and TNF in LPS activated human monocytes. Cytokine 1994; 6: 564.
77. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-47.
78. Galcheva-Gargova Z, Dérijard B, Wu I-H, et al. An osmosensing signal transduction pathway in mammalian cells. Science 1994; 265: 806-9.
79. Han J, Lee J-D, Bibbs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-11.
80. Lin T-A, Kong X, Haystead TAJ, et al. PHAS-I as a link between mitogen activated proetin kinase and translation initiation. Science 1994; 266: 653-5.
81. Ferretti M, Casini-Raggi V, Pizarro TT, et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94: 449-53.
82. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
83. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of interleukin-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492-9.
84. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effect of IL-4: IL-4 down regulates IL-1 synthesis but up regulates IL-1ra production. Proc Natl Acad Sci (USA) 1992; 89: 4076-80.
85. Chantry D, Turner M, Abney E, et al. Modulation of cytokine production by transforming growth factor-beta. J Immunol 1989; 142: 4295-300.
86. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167-227.
87. Dripps DJ, Brandhuber BJ, Thompson RC, et al. Effect of IL-1ra on IL-1 signal transduction. J Biol Chem 1991; 266: 10331-6.
88. Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 1987; 139: 1546-9.
89. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-40.
90. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-6.
91. Granowitz EV, Porat R, Mier JW, et al. Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993; 82: 2985-2990.
92. Granowitz EV, Santos, A, Poutsiaka DD, et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 1991; 338: 1423-4.
93. Hyams JS, Fitzgerald JE, Wyzga N, et al. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994; 39: 1893-9.
94. Mandrup-Poulsen T, Wogcnsen L, Jensen M, et al. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Crit Care Med 1995; 23: 26-33.
95. Tilg H, Trehu E, Shapiro L, et al. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin-1α infusion in humans. Cytokine 1994; 6: 215-9.
96. Bargetzi MJ, Lantz M, Smith CG, et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding proteins. Cancer Res 1993; 53: 4010-3.
97. Miller LC, Lynch EA, Isa S, et al. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993; 341: 146-8.
98. Chensue SW, Bienkowski M, Ecssalu TE, et al. Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. J Immunol 1993; 151: 3654-62.
99. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, saftey, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353-60.
100. Granowitz EV, Clark BD, Vannier E, et al. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992; 79: 2356-63.
101. Fisher CJJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
102. Gershenwald JE, Fong YM, Fahey TJ, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990; 87: 4966-70.
103. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
104. Fisher CJJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial. JAMA 1994; 271: 1836-43.
105. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs for sepsis. JAMA 1993; 270: 1233-41.
106. Lebsack ME, Paul CC, Bloedow DC, et al. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthr Rheumatol 1991; 34 (suppl): S67.
107. Lebsack ME, Paul CC, Martindale JJ, et al. A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthr Rheumat 1993; 36: S39.
108. Bresnihan B, Lookabaugh J, Witt K, et al. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial (abstract). Arthrit Rheumat 1996; 39: S73.
109. Watt I, Cobby M. Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis. Arthrit Rheumat 1996; 39: S123.
110. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-8.
111. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by interleukin-1 receptor antagonist prevents graft versus host disease. Blood 1991; 78: 1915-8.
112. Arend WP, Malyak M, Smith MF, et al. Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994; 153: 4766-74.
113. Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II IL-1 receptor in sepsis. J Immunol 1994; 153: 5802-13.
114. Orencole SF, Vannier E, Dinarello CA. Detection of soluble IL-1 receptor type II (IL-IsRII) in sera and plasma from healthy volunteers (abstract). Cytokine 1994; 6: 554.
115. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739-42.
116. Dower SK, Fanslow W, Jacobs C, et al. Interleukin-1 antagonists. Therapeutic Immunol 1994; 1: 113-22.
117. Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J Immunol 1991; 146: 2983-9.
118. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-6.
119. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990; 265: 14497-504.
120. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974-80.
121. Olsson I, Gatanaga T, Gullberg U, et al. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Net 1993; 4: 169-80.
122. Chikanza IC, Roux-Lombard P, Dayer JM, et al. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92: 19-22.
123. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor α and soluble TNF receptor concentrations in severe meningococcemia. Immunology 1992 (in press).
124. Shapiro L, Clark BD, Orencole SF, et al. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344-50.
125. van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-9.
126. Jansen J, van der Poll T, Levi M, et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by anti-tumor necrosis factor antibody. J Clin Immunol 1995 (in press).
127. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis in cancer patients. Cancer Res 1991; 51: 5602-7.
128. Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-9.
129. Lesslauer W, Tabuchi H, Gentz M, et al. Recombinant soluble TNF receptor proteins inhibit LPS-induced lethality in mice (abstract). Cytokine 1991; 3: 497.
130. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-6.
131. Porat R, Paddock HN, Schwaitzberg SD, et al. Glycosylated recombinant human TNF binding protein-1 reduces mortality, shock and production of TNF in rabbit Escherichia coli sepsis. Crit Care Med 1995 (in press).
132. Bertini R, Delgado R, Faggioni R, et al. Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. Eur Cytokine Netw 1993; 4: 39-42.
133. Opal SM. Clinical trials of novel therapeutic agents: why did they fail? In: Vincent JL, ed. Clinical trials of novel therapeutic agents: why did they fail? Berlin: Springer Verlag, 1995; 425-36.
134. Elliott MJ, Maim RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
135. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
136. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273: 934-41.